New HPV vaccine gives consumers another choice


Vinti Singh, Staff Writer
Published: 08:09 p.m., Tuesday, June 1, 2010

DANBURY — Adolescent girls and young women now have another option besides Gardasil if they choose to get a vaccine to protect against the human papillomavirus, which causes cervical cancer.

The U.S. Food and Drug Administration approved a new vaccine — Cervarix — last October. The vaccine has been approved in the United Kingdom since 2007 and is manufactured by the pharmaceutical company GlaxoSmithKline.

Since Gardasil — an HPV vaccine produced by Merck — was approved in 2006, it has been hailed by the medical community as safe and having the potential to eradicate cervical cancer.

But an undercurrent of opposition, led mostly by mothers whose daughters experienced adverse effects after getting vaccinated, has repeatedly questioned if the side effects outweigh the benefits of the vaccine.

As a relatively new vaccine, Cervarix has not been vetted as thoroughly in the media.

GlaxoSmithKline has given groups in four different states millions of dollars to fund “educational campaigns that will increase voluntary vaccinations,” according to The News & Observer of Raleigh, N.C.

The Cervarix vaccine, injected in three doses over a six-month period, is meant to protect against two strains of the human papillomavirus, types 16 and 18. Seventy-five percent of cervical cancers in North America are caused by these two strains, according to GlaxoSmithKline.


VAERS reports are showing even more severe side effects from Cervarix than Gardasil……


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.